Title page

The Role of CRP, Interleukin-6 and Their Derived Immune-Inflammatory Indices in Early Prediction of Severity and Mortality of COVID-19 Patients

Running title: CRP, IL-6 and their indices in COVID-19

Sara I. Taha [1]*, Aalaa K. Shata [2], Shereen A. Baioumy [3], Shaimaa H. Fouad [4], Aya H. Moussa [5], Shaimaa A. Abdalgeleel [6] and Mariam K. Youssef [7]

1. Department of Clinical Pathology/Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
   E-mail: dr_sara_ib@med.asu.edu.eg   ORCID: https://orcid.org/0000-0001-8224-8701
2. Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.
   E-mail: aalaashata@yahoo.com
3. Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
   Email: drshereenatef@yahoo.com   ORCID: https://orcid.org/0000-0002-2188-6790
4. Department of Internal Medicine / Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. E-mail: shaimaahani@med.asu.edu.eg   ORCID: https://orcid.org/0000-0003-4052-9454
5. Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo, Egypt. E-mail: Ayahisham@med.asu.edu.eg   ORCID: https://orcid.org/0000-0003-4680-2204
6. Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.
   E-mail: shaimaa.abdalgeleel@nci.cu.edu.eg   ORCID: https://orcid.org/0000-0003-0994-7703
7. Department of Clinical Pathology/Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
   E-mail: Dr.mariam_karam@hotmail.com   ORCID: https://orcid.org/0000-0003-2075-3889

* Corresponding Author:

Sara Ibrahim Taha, MD, PhD

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University.

Address: Ain Shams University, Abassia, Cairo, Egypt

Office tel., fax: + (202) 24346308   Mobile: + (20) 1125360009

E-mail: dr_sara_ib@med.asu.edu.eg

https://orcid.org/0000-0001-8224-8701

Abstract:

Background: In coronavirus disease 2019 (COVID-19), finding sensitive biomarkers is critical for detecting severe cases early and intervening effectively. **Objectives:** To compare and evaluate the predictive value of C-reactive protein (CRP), interleukin-6 (IL-6), and their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in COVID-19 patients. **Methods:** On admission, 85 confirmed COVID-19 patients' measured and collected laboratory data were obtained and compared. **Results:** Levels of CRP, IL-6, and CRP/alb were significantly higher (P=0.001) in severe patients and non-survivors, but L/CRP and L/IL-6 were significantly lower (P=0.001). The best predictive performance for COVID-19 severity was observed at 1.65 for CRP/alb and 260.86 for L/CRP with 84.7% diagnostic accuracy for both. The best diagnostic accuracy for COVID-19 in-hospital mortality was 87.1% by IL-6 at 120 pg/ml and 85.9% by L/IL-6 at 5.40. The performance of the combined prediction was better than the single prediction by one biomarker. IL-6 was an independent risk factor associated with severe disease development (odds ratio: 1.033; 95% confidence interval: 1.002-1.066). **Conclusions:** Pretreatment values of CRP, IL-6, and their derived indices could be included in the diagnostic work-up of COVID-19 to stratify disease severity and predict outcomes.

Keywords: *COVID-19; CRP; Interleukin-6; Mortality; Ratio; Severity*

Introduction:

A global pandemic of coronavirus illness 2019 (COVID-19) is presently sweeping the globe, affecting millions of individuals.[1] COVID-19 is more contagious than seasonal influenza, has a longer incubation time, and is linked to a greater hospitalization rate and overall mortality. The virus can be transmitted through the respiratory tract, causing a respiratory infection that can rapidly develop into severe pneumonia, respiratory distress, multi-organ failure, and even death.[2] Although most COVID-19 patients recover quickly after the appropriate clinical intervention, the moderate type patients, particularly the elderly, obese patients, and those with comorbidities, can rapidly worsen and become severe, increasing ICU admission and mechanical ventilation, indicating a high mortality rate.[3] Thus, early identification of potentially severe patients is critical for halting disease progression at an early stage.

Previous studies have found that aberrant immune-inflammatory response and cytokine storm may play an important role in COVID-19 progression.[4] Therefore, this study was performed to assess the predictive efficacy of individual and combination baseline inflammatory indicators; C-reactive protein (CRP) and interleukin-6 (IL-6) together with their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in a cohort of Egyptian COVID-19 patients.

Materials & methods:

Patients:

This cohort observational study included eighty-five COVID-19 patients (aged ≥ 18 years) from the Hospitals of Ain-Shams University in Cairo, Egypt, between March and May 2021. COVID-19 was confirmed in all of the patients by a real-time polymerase chain reaction test. The study excluded pregnant women and patients with hematological diseases, immunodeficiencies, or

autoimmune disorders. The COVID-19 management guideline supplied by Ain Shams University Hospitals was used to classify the patients according to their disease severity.[5]

Data collection:

From medical records, epidemiological and clinical data (such as age, sex, underlying diseases or comorbidities, length of hospital stay, need for ICU admission, and patients' outcomes) were collected, as well as laboratory findings from the same day (such as complete blood differential counts and CRP). Patients were followed up on until they were discharged from the hospital or had an in-hospital death.

Blood sampling and analysis:

Venous blood samples were taken via venipuncture from all enrolled patients into biochemistry tubes covered with gel for serum separation. The samples were allowed to clot for 30 mins before being centrifuged for 10 mins at 2,500 g. The serum was immediately used to determine albumin level using a Beckman Coulter AU480 autoanalyzer (Beckman Coulter, Inc. 250s. Kraemer Blvd. Brea, CA92821, USA), according to instructions of the Operator's Manual. The dynamic range of albumin was 1.5-6.0 g/dL. The remaining sera were kept at -80°C until they were tested for IL-6 using a commercially available Human IL-6 ELISA Kit from RayBiotech Life, Inc., GA, USA [CODE: ELH-IL6-1]. According to the manufacturer's instructions, the assay was carried out with a detection range of 3 pg/ml - 1000 pg/ml.

Calculations:

Derived immune-inflammatory indices were calculated as follows: L/CRP = lymphocyte (number/μl)/CRP (mg/dl); L/IL-6 = lymphocyte (number/μl)/IL-6 (pg/ml); CRP/alb = CRP (mg/dl)/albumin (g/dl).

Statistical analysis:

Statistical analysis was performed using SPSS 20.0 (IBM Corporation, NY, USA). Descriptive statistics were done using median and percentiles for quantitative nonparametric measures, while categorized data were described in numbers and percentages. Comparisons were made using the Wilcoxon Rank Sum test and Chi-square test. The predictive performance of each pretreatment biomarker alone and the clinical benefit of biomarkers combinations were assessed by the receiver operating characteristic (ROC) curve. The odds ratio (OR) and 95% confidence interval (CI) were calculated using logistic regression analysis. The significant probability of error was set at 0.05.

Results:

Demographic and Clinical Characterization of the Study Cohort

The 85 patients included in this prospective cohort study comprised 48 (56.5%) males and 37 (43.5%) females with a median (IQR) age of 55 years (42 – 65). Of all, 54.1% (n=46) were non-severe while 45.9% (n=39) were severe. The most prevalent presenting symptoms were dyspnea (51.8%) and fever (40%). Hypertension (40.0%) and diabetes mellitus (36.5%) were the most common associated comorbidities. The median (IQR) duration of hospitalization was 10 days (6 – 17), during which 38.8% (n=33) of patients required ICU admission, and 24.7% (n=21) died. Baseline characteristics and laboratory findings of the studied population (n=85) are demonstrated in **table 1.**

Characteristics of COVID-19 patients according to disease severity and in-hospital mortality:

Table 2 compares the baseline clinical characteristics and laboratory findings according to the severity and in-hospital mortality of COVID-19 patients.

Significant changes between the severity groups were observed when their median (IQR) values were compared. As opposed to the non-severe group, severe patients had significantly higher

values of CRP (129 (IQR: 50 – 152) vs.12 (6.5 – 32) mg/L; P ≤ 0.001), IL-6 (120 (80 – 220) vs. 32 (18 – 50) pg/ml; P ≤ 0.001) and CRP/alb (3.87 (1.66 – 4.90) vs. 0.35 (0.15 – 0.64); P ≤ 0.001). And, significantly lower values of L/CRP (105.26 (56.96 – 230.26) vs. 1211.96 (449.82 – 2500); P ≤ 0.001), L/IL-6 (8.33 (4.20 – 14.54) vs. 40.83 (25.20 – 98.71); P ≤ 0.001), lymphocyte count (0.9 (0.5 – 2.2) vs.1.49 (1 – 2.22) ×103/µL; P=0.028) and albumin (3.2 (2.9 – 3.6) vs. 4 (3.1 – 4.8) g/dl; P ≤ 0.001).

Regarding in-hospital mortality of COVID-19, significant differences between survivors and non-survivors were observed. CRP (152 (57.8 – 152) vs.18 (7.7 – 65.75) mg/L;P ≤ 0.001), IL-6 (168 (110 – 275) vs. 45 (20 – 97.5) pg/ml; P ≤ 0.001), and CRP/alb (4.3 (1.82 – 5.52) vs. 0.52 (0.20 – 1.70); P ≤ 0.001) showed significantly higher values in non-survivors compared to survivors. In contrast, L/CRP (105.26 (43.56 – 212.5) vs. 703.27 (186.18 – 2005.35); P ≤ 0.001), L/IL-6 (5.33 (3.34 – 14.55) vs. 29.55 (11.90 – 79); P ≤ 0.001) and albumin (3 (2.75 – 3.6) vs. 3.75 (3.02 – 4.35) g/dl; P= 0.001) were significantly lower. But, the change in lymphocyte count according to in-hospital mortality was not significant (0.9 (0.55 – 1.96) vs.1.4 (0.77 – 2.2) ×103/µL; P=0.178).

Predictive performance evaluation:

Table 3: demonstrates diagnostic validity tests and ROC curve analysis used to assess each biomarker's overall prognostic performance on its own, identifying those that performed well. Biomarkers with the best diagnostic efficacies (least false and highest true results) were then combined in a multi-ROC curve to maximize the AUC and improve predictive accuracy.

Regarding COVID-19 severity, while CRP alone at a cut-off of 48 mg/L offered 0.861 AUC and 82.4% diagnostic accuracy, its derived indices, CRP/alb, and L/CRP, exhibited the best predictive performance compared to other biomarkers. At the cut-off point of 1.65 for CRP/alb and 260.86 for L/CRP, the AUC was 0.878 and 0.873, respectively, and the diagnostic accuracy

was 84.7% for both. And when CRP/alb at a cut-off point of 1.65 was combined with L/CRP at a cut-off point of 2300 in a multi-ROC analysis, COVID-19 severity prediction accuracy increased to 95.3% with an AUC of 0.922. **Figure 1**

Concerning COVID-19 in-hospital mortality, the baseline IL-6 level was the most highly predictive biomarker with 0.88 AUC at a cut-off point of 120 pg/ml and diagnostic accuracy of 87.1%. Comparable to IL-6 was L/IL-6 with 0.86 AUC at a cut-off point of 5.40 and a diagnostic accuracy of 85.9%. Adding IL-6 at a cut-off point of 120 pg/ml to L/IL-6 at a cut-off point of 8 has improved the overall in-hospital mortality prediction ability and increased the AUC to 0.946 and the diagnostic accuracy to 96.5%. **Figure 2**

Risk factors assessment:

The association between IL-6, CRP, and their derived indices with COVID-19 severity and in-hospital mortality was further evaluated by logistic regression analysis. As to COVID-19 in-hospital mortality, the multivariate analysis showed that the odds ratios (ORs) of all studied biomarkers were not significantly different between survivors and non-survivors (p > 0.05). And only IL-6 was an independent risk that was significantly positively associated with severe disease development (OR: 1.033; 95% CI: 1.002 - 1.066; P =0.037). **Table 4** demonstrates univariate and multivariate logistic regression analyses for possible predictors of COVID-19 severity and in-hospital mortality.

Discussion:

During the current pandemic of COVID-19, since immune dysfunction, hyper-inflammation, and hyper-cytokinaemia have been closely related to the rapid progression of the disease,[6] continuous finding of sensitive inflammatory biomarkers for timely and effective identification of disease progression is necessary.[7]

CRP is a helpful inflammatory biomarker that aids in the resistance of invading pathogens in the host. In COVID-19 patients, it was revealed to be strongly linked to acute lung damage. Furthermore, greater CRP levels have been connected to negative characteristics of the disease, including heart damage, respiratory difficulty, and even death. As a result, detecting CRP levels is quite helpful in determining the severity of COVID-19 patients.[8]

In our study, CRP increased significantly with COVID-19 severity and in-hospital mortality. Similarly, several studies have reported significantly higher CRP values in the more severe patients and those who died from the disease.[8-10] On the contrary, Zhang Y. revealed no significant change in CRP levels in patients after being admitted to ICU.[11] Also, Ferrari and colleagues, based on statistical analysis, stated that CRP might not be very useful in discriminating between patients with or without COVID-19.[12]

IL-6 is a multifunctional cytokine that regulates immunological and inflammatory responses. It has been found to play a key role in the development and progression of coronavirus pneumonia. In COVID-19 patients with the hyper-inflammatory syndrome, circulating IL-6 concentrations have been linked to disease severity, the incidence of acute lung damage, and the need for mechanical ventilation, suggesting that measuring IL-6 levels can help guide therapy decisions.[13]

In our study, IL-6 levels were significantly higher in severe patients and non-survivors. Per our results, Sun and co-workers reported significantly higher IL-6 values in the more severe patients.[13] Also, Coomes and Haghbayan have reported in a systemic review that IL-6 was associated with adverse outcomes in COVID-19 patients.[14]

Furthermore, several studies have reported the distinct clinical significance of IL-6 at varying cut-off values. Gao et al. studied a cohort of 43 cases and reported that combining IL-6 at a cut-off value of 24.3 pg/ml with the D-Dimer helped in the early detection of severe cases.[15] In another cohort by Giofoni et al., serum IL-6 at a cut-off value of 25 pg/ml represented an

independent risk of progression to severe disease and/or in-hospital mortality.[16] In a cohort study of 40 patients in Munich, COVID-19 patients' need for mechanical ventilation increased 22 times with the elevated IL-6 levels (> 80 pg/ml).[17]

In a meta-analysis, Coomes and Haghbayan discovered statistical heterogeneity in IL6 levels in subjects with varying degrees of disease severity. They attributed this to inconsistencies of patients' characteristics in each trial and discrepancies in the timing of IL6 testing and immunomodulatory medicines received.[14]

Significant hypo-albuminemia and lymphopenia were discovered in severe patients in the current study; however, only significant hypo-albuminemia and not lymphopenia was detected in non-survivors. Returning to the fact that albumin levels drop in inflammatory conditions, hypoalbuminemia has been noted in COVID-19 patients with severe hyperinflammation.[18]

In several studies,[3, 19] COVID-19 severity and progression have been linked to lymphopenia, a reliable and accurate prediction. According to a meta-analysis study, the more serious the condition, the fewer lymphocytes there were [20], which could be attributed to the disease's effect on T cell subsets, resulting in immunological dysfunction.[21,22] Several studies have emphasized that when the lymphocyte count is less than 1.5 10^3/µL, lymphopenia should be addressed.[9]

Using an inflammatory biomarker alone to evaluate patients infected with COVID-19 could be influenced by several factors. As a result, the generated indices from the most important inflammatory biomarkers may more accurately and thoroughly indicate immunological dysregulation.[7, 23]

The L/CRP has been used as a prognostic marker for several cancers, including colon and gastric carcinomas. The rationale behind this is that it serves as a good indicator of the complex host-tumor immunological interactions that result in the systemic inflammatory process incriminated in the pathogenesis of these carcinomas.[24-26] COVID-19 also triggers an inflammatory reaction

throughout the body; therefore, the L/CRP could be a useful prognostic biomarker for disease severity and outcome. On exploring the role of L/CRP in the prognosis of our studied COVID-19 patients, we found that it declined significantly with the increase in disease severity and mortality. By our results, Ullah and co-workers have found that a low L/CRP was a good predictor of in-hospital complications and mortality in COVID-19 patients. [24]

High CRP/alb was previously linked to mortality in critically ill patients of various conditions.[27] In our study, we found a significant elevation of the CRP/alb as the disease progressed. Similarly, El-Shabrawy and colleagues have found that the CRP/alb was a predictive factor of COVID-19 mortality.[28]

In our study, the L/IL-6 was much lower in severe COVID-19 patients and non-survivors. In the same context, because high IL-6 levels and low lymphocyte counts have been connected to the severity and in-hospital mortality of COVID-19, in a study by Yang and colleagues, the IL-6/lymphocyte ratio (IL-6/L, reversed) was described as a novel biomarker to conduct risk stratification in COVID-19 patients.[7] Other studies have found that having a high IL-6/L is an independent risk factor for disease progression and a poor prognosis.[29, 30] The decrease in lymphocyte numbers caused by IL-6-mediated inhibition of T cell activation explained the high in COVID-19.[31] Furthermore, in a study by Liu et al., T cell numbers were inversely associated with the studied cytokine levels, including IL-6.[32] As a result, the balance of IL-6 and lymphocytes appeared to play a critical role in the regulation of the immune system.

ROC curve analysis was used to assess the overall predictive performance of each biomarker alone. Then, in a multi-ROC curve analysis, we integrated biomarkers that exhibited the best predictive performance for COVID-19 severity or in-hospital mortality to achieve the maximum overall test efficacy and improve the predictive ability. The combination of CRP/alb and L/CRP improved disease severity prediction accuracy. Similarly, combining IL-6 with the L/IL-6

enhanced in-hospital mortality prediction accuracy. Finally, only IL-6 was positively correlated with disease severity, but none of the investigated biomarkers were shown to be an independent predictor of in-hospital mortality. This could be attributed to the small sample size and the disproportion between the study groups, and these were the study's major limitations.

More research on a larger scale and for a longer period is needed to determine the predictive usefulness of the proposed inflammatory indices compared to the other existing biomarkers to slow the disease's progression and put the epidemic to an end.

Conclusions:

The current study discovered that CRP and IL-6 and their derived immune-inflammatory indices, namely CRP/alb, L/CRP, and L/IL-6, were good predictors of COVID-19 severity and in-hospital mortality. Using these indicators in combinations rather than a single biomarker alone would improve the overall performance in disease progression prediction.

Abbreviations:

CRP/alb: CRP/albumin; L/CRP: lymphocyte/CRP; L/IL-6: lymphocyte/IL-6

Acknowledgement: None.

Authors' contribution:

All authors contributed significantly to this work, whether it was in the conception, study design, data acquisition, analysis, and interpretation, or in the drafting, revising, or reviewing of the article, and they all provided final approval of the version to be published.

Data availability statement: On reasonable request, the corresponding author will provide the datasets used and/or analyzed during the current work.

Conflicts of interest disclosure: The author(s) declared no potential conflicts of interest.

Funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics: Ethical approval for the current study protocol was obtained from Ain Shams University Faculty of Medicine Research Ethics Committee (REC) FWA 00017585. All patient data were kept private and confidential. Solely utilized them for research purposes.

Statement of informed consent: All procedures were explained to all participants or their first-degree relatives, with informed consent obtained from them.

Consent for publication: Not applicable**.**

References:

1. Chan AS, Rout A (2020) Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. *J Clin Med Res.* 12(7):448-453.

2. Feng X, Li S, Sun Q, et al (2020) Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. *Front Med (Lausanne).* [online] 7:301. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295898/pdf/fmed-07-00301.pdf [Accessed 9 Jan. 2021].

3. Tan L, Wang Q, Zhang D, et al (2020) Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther*. 5(1):33.

4. Zhu Z, Cai T, Fan L, et al (2020) Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. *Int J Infect Dis.* 95:332-339.

5. Badawy Abdelfattah E, Ahmed El-Zahapy H, El Said A, et al (2020) Hospital response to COVID-19 a consensus: Report on Ain Shams University Hospital Strategy. *ScienceOpen* [published online ahead of print].

6. Mehta P, McAuley DF, Brown M, et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 395 (10229):1033-1034.

7. Yang B, Chang X, Huang J, et al (2021) The role of IL-6/Lin the peripheral blood of severe patients with COVID-19. *Int Immunopharmacol.* 97:107569.

8. Shang W, Dong J, Ren Y, et al (2020) The value of clinical parameters in predicting the severity of COVID-19. *J Med Virol*. 92 (10):2188-2192.

9. Kazemi E, Soldoozi Nejat R, Ashkan F, et al (2021) The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis. *Ann Clin Microbiol Antimicrob*. 20 (1):17.

10. Danwang C, Endomba FT, Nkeck JR, et al (2020) A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). *Biomark Res*. 8:37.

11. Zhang Y, Zheng L, Liu L, et al (2020) Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single center in Wuhan city, China. *Liver*.40(9):2095-2103.

12. Ferrari D, Motta A, Strollo M, et al (2020) Routine blood tests as a potential diagnostic tool for COVID-19. *Clin Chem Lab Med*. 58(7):1095–1099.

13. Sun H, Guo P, Zhang L, et al (2020) Serum Interleukin-6 Concentrations and the Severity of COVID-19 Pneumonia: A Retrospective Study at a Single Center in Bengbu City, Anhui Province, China, in January and February 2020. *Med Sci Monit*. 26: e926941.

14. Coomes EA and Haghbayan H (2020) Interleukin-6 in COVID-19: a systematic review and meta-analysis. *Rev Med Virol*. 30(6): 1-9.

15. Gao Y, Li T, Han M, et al (2020) Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol*. 92(7):791-796.

16. Grifoni E, Valoriani A, Cei F, et al (2020) Interleukin-6 as prognosticator in patients with COVID-19. *J Infect*. 81(3):452-482.

17. Herold T, Jurinovic V, Arnreich C, et al (2020) Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. *medRxiv* (preprint).

18. Aziz M, Fatima R, Lee-Smith W, et al (2020) The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. *Crit Care*. 24(1):255.

19. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al (2020) Hematological findings and complications of COVID-19. *Am J Hematol*. 95(7):834-847.

20. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, et al (2020) Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta*. 510:475–82.

21. Tufan A, Güler AA, Matucci-Cerinic M. (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 50(SI-1):620-632.

22. Wang F, Nie J, Wang H, et al (2020) Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis*. 221(11):1762-1769.

23. Sun Y, Dong Y, Wang L, et al (2020) Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *J Autoimmun*. 112: 102473.

24. Ullah W, Basyal B, Tariq S, et al (2020) Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. *J Clin Med Res*. 12(7):415-422.

25. Okugawa Y, Toiyama Y, Yamamoto A, et al (2020) Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-in-flammation markers of outcome in patients with gastric cancer. *Clin Nutr*. 39(4):1209-1217.

26. Okugawa Y, Toiyama Y, Yamamoto A, et al (2020) Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. *Ann Surg*. 272(2):342-351.

27. Akirov A, Masri-Iraqi H, Atamna A, et al (2020) Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. *Am J Med*. 133(5):646.

28. El-Shabrawy M, Alsadik ME, El-Shafei M, et al (2021) Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. *Egypt J Bronchol.* 15(1):5.

29. Chen X, Zhao B, Qu Y, et al (2020) Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID- 19 patients. *Clin Infect Dis.* 71(8):1937-1942.

30. Chiappelli F, Khakshooy A, Greenberg G (2020) COVID-19 Immunopathology and Immunotherapy. *Bioinformation.* 16 (3) 219 – 222.

31. Guan W, Ni Z, Hu Y, et al (2020) Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 382:1708-1720.

32. Liu J, Li S, Liu J, et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients *EBioMedicine.* 55:102763.

Figure 1: ROC curve analysis showing the diagnostic performance of CRP/alb (AUC:0.878; 95%CI: 0.805-0.952); L/CRP (AUC: 0.873; 95%CI: 0.798-0.948) and their combination (AUC: 0.922) for discriminating severe COVID-19 patients from those non-severe.

Figure 2: ROC curve analysis showing the diagnostic performance of L/IL-6 (AUC: 0.866; 95CI: 0.762-0.970); IL-6(AUC: 0.888; 95CI: 0.819-0.957), and their combination (AUC: 0.946) for discriminating survivors from non-survivors in COVID-19.

Table 1: Baseline characteristics and laboratory findings of the studied population (n=85)**.**

Variable		All Cases (n=85)
Age (years)	Median (IQR)	55 (42 – 65)
	Range	21 – 85
Sex n, (%)	Male	48 (56.5%)
	Female	37 (43.5%)
Comorbidities n, (%)	DM	31 (36.5%)
	HTN	34 (40.0%)
	COPD	7 (8.2%)
	IHD	5 (5.9%)
	CLD	3 (3.5%)
	CKD	15 (17.6%)
Symptoms n, (%)	Cough	1 (1.2%)
	Cough and dyspnea	2 (2.4%)
	diarrhea	1 (1.2%)
	Dyspnea	44 (51.8%)
	fever	34 (40.0%)
	Fever and Cough	3 (3.5%)
ICU admission n, (%)	Positive	33 (38.8%)
	Negative	52 (61.2%)
Severity n, (%)	Non-severe	46 (54.1%)
	severe	39 (45.9%)
Laboratory findings Median (IQR)	Hemoglobin gm/dl	12.6 (10.2 – 14.2)
	Platelets $\times 10^3$/cmm	227 (171.5 – 273.5)
	Total leukocytic count $\times 10^3$/cmm	6.9 (4.35 – 10.55)
	Lymphocytes $\times 10^3$/cmm	1.34 (0.7 – 2.2)
	Neutrophils $\times 10^3$/cmm	4.28 (2.39 – 7.86)
	Albumin (g/dl)	3.5 (3 – 4.2)
	CRP (mg/L)	32 (9.5 – 132.5)
	IL– 6 (pg/ml)	55 (25 – 120)
	L/CRP	348.83 (99.78 – 1545.32)
	CRP/alb	0.94 (0.28 – 3.87)
	L/IL-6	18.97 (8.25 – 51.71)
Hospital stay (days)	Median (IQR)	10 (6 – 17)
	Range	(2 – 30)
Fate	Discharged	64 (75.3%)
	Died	21 (24.7%)

CKD: Chronic kidney disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HTN: Hypertension; ICU: Intensive care unit; IHD: Ischemic heart disease; IQR: interquartile range.

Table 2: Comparisons of baseline characteristics and laboratory findings according to COVID-19 severity and in-hospital mortality.

Variable		Non–severe (n=46)	Severe (n=39)	p–value	Survivors (n=64)	Non–survivors (n=21)	p–value
Age (years)	Median (IQR)	55.5 (41.5 – 63)	55 (43 – 67)	0.250	55.5 (42 – 64.75)	55 (47 – 69.5)	0.454
Sex n, (%)	Male	23 (50.0%)	25 (64.1%)	0.191	34 (53.1%)	14 (66.7%)	0.277
	Female	23 (50.0%)	14 (35.9%)		30 (46.9%)	7 (33.3%)	
Comorbidities n, (%)	DM	13 (28.3%)	18 (46.2%)	0.088	19 (29.7%)	12 (57.1%)	0.023
	HTN	15 (32.6%)	19 (48.7%)	0.131	22 (34.4%)	12 (57.1%)	0.065
	COPD	2 (4.3%)	5 (12.8%)	0.157	3 (4.7%)	4 (19.0%)	0.038
	IHD	0 (0.0%)	5 (12.8%)	0.012	3 (4.7%)	2 (9.5%)	0.414
	CLD	2 (4.3%)	1 (2.6%)	0.657	3 (4.7%)	0 (0.0%)	0.312
	CKD	4 (8.7%)	11 (28.2%)	0.019	10 (15.6%)	5 (23.8%)	0.393
Laboratory parameters Median (IQR)	Lymp $\times 10^3$/cmm	1.49 (1 – 2.22)	0.9 (0.5 – 2.2)	0.028	1.4 (0.77 – 2.2)	0.9 (0.55 – 1.96)	0.178
	CRP (mg/L)	12 (6.5 – 32)	129 (50 – 152	≤ 0.001	18 (7.7 – 65.75)	152 (57.8 – 152)	≤ 0.001
	Albumin (g/dl)	4 (3.1 – 4.8)	3.2 (2.9 – 3.6)	≤ 0.001	3.75 (3.02 – 4.35)	3 (2.75 – 3.6)	0.001
	IL–6 (pg/ml)	32 (18 – 50)	120 (80 – 220)	≤ 0.001	45 (20 – 97.5)	168 (110 – 275)	≤ 0.001
	L/IL-6	40.83 (25.20 – 98.71)	8.33 (4.20 – 14.54)	≤ 0.001	29.55 (11.90 – 79)	5.33 (3.34 – 14.55)	≤ 0.001
	CRP/alb	0.35 (0.15 – 0.64)	3.87 (1.66 – 4.90)	≤ 0.001	0.52 (0.20 – 1.70)	4.3 (1.82 – 5.52)	≤ 0.001
	L/CRP	1211.96 (449.82 – 2500)	105.26 (56.96 – 230.26)	≤ 0.001	703.27 (186.18 – 2005.35)	105.26 (43.56 – 212.5)	≤ 0.001
ICU admission n, (%)	Positive	9 (19.6%)	24 (61.5%)	≤ 0.001	17 (26.6%)	16 (76.2%)	≤ 0.001
	Negative	37 (80.4%)	15 (38.5%)		47 (73.4%)	5 (23.8%)	
Hospital stay (days)	Median (IQR)	10.5 (6.75 – 17.5)	9 (5 – 14)	0.112	9.5 (6 – 17)	10 (7 – 16)	0.759
Fate	Discharged	43 (67.2%)	21 (32.8%)	≤ 0.001			
	Died	3 (14.3%)	18 (85.7%)				

CKD: Chronic kidney disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HTN: Hypertension; ICU: Intensive care unit; IHD: Ischemic heart disease; IQR: Interquartile range; Lymp: Lymphocytes. Statistical significance set at 0.05.

Table 3: Diagnostic validity and receiver operating curve (ROC) analysis for the ability of CRP, IL-6 and their derived indices to distinguish COVID-19 infected patients according to severity and mortality of the disease

Indicators	Cut off	AUC	Specificity %	Sensitivity %	NPV %	PPV %	Accuracy %
Severity							
CRP	48	0.861	84.8	79.5	83.0	81.6	82.4
IL– 6	50	0.873	78.3	87.2	87.8	77.3	82.4
L/IL-6	11.66	0.883	95.7	71.8	80.0	93.3	84.7
CRP/alb	1.65	0.878	91.3	76.9	82.4	88.2	84.7
L/CRP	260.86	0.873	89.1	79.5	83.7	86.1	84.7
CRP/alb at 1.65 + L/CRP at:2300	--	0.922	91.3	100.0	100.0	90.7	95.3
In- hospital mortality							
CRP	151	0.801	92.2	57.1	86.8	70.6	83.5
IL– 6	120	0.888	92.2	71.4	90.8	75.0	87.1
L/IL-6	5.40	0.866	95.3	57.1	87.1	80.0	85.9
CRP/alb	4.21	0.812	90.6	57.1	86.6	66.7	82.4
L/CRP	129.03	0.787	79.7	61.9	86.4	50.0	75.3
IL-6 at 120 pg/ml + L/IL-6 at:8	--	0.946	100.0	85.7	95.5	100.0	96.5

AUC: area under curve; CRP/alb = CRP (mg/dl)/albumin (g/dl); CRP: C-reactive protein in mg/L; IL-6: interleukin-6 in pg/mL; L/CRP = lymphocyte (number/μl)/CRP (mg/dl); L/IL-6 = lymphocyte (number/μl)/IL-6 (pg/ml); NPV: negative predictive value; PPV: positive predictive value.

Table 4: Logistic regression analysis for predictors of COVID-19 severity and in-hospital mortality

Indicator	Uni-variate				Multi-variate			
	P-value	**Odds ratio**	**95% C.I. for OR**		**P-value**	**Odds ratio**	**95% C.I. for OR**	
			Lower	**Upper**			**Lower**	**Upper**
Mortality								
L/IL-6	**0.001**	0.872	0.803	0.947	0.374	0.92	0.766	1.105
CRP/alb	**≤ 0.001**	1.921	1.431	2.579	0.439	2.602	0.231	29.268
L/CRP	**0.065**	0.999	0.999	1	0.164	1	1	1.001
CRP (mg/L)	**≤ 0.001**	1.021	1.011	1.031	0.758	0.988	0.917	1.065
IL– 6 (pg/ml)	**≤ 0.001**	1.019	1.01	1.028	0.152	1.013	0.995	1.032
Severity								
L/IL-6	**0.001**	0.945	0.914	0.976	0.652	1.006	0.981	1.032
CRP/alb	**≤ 0.001**	2.787	1.821	4.264	0.371	7.401	0.092	593.008
L/CRP	**≤ 0.001**	0.997	0.996	0.999	0.285	0.999	0.996	1.001
CRP (mg/L)	**≤ 0.001**	1.03	1.018	1.043	0.495	0.956	0.84	1.088
IL– 6 (pg/ml)	**≤ 0.001**	1.032	1.018	1.047	**0.037**	1.033	1.002	1.066

CI: Confidence interval